• 肽瑞禾

腫瘤胜肽疫苗研發 | 從普及化到個人化​​

更新日期:6月 2


(圖片來源)

引用 | Wiley Online Library報導


Development of tumour peptide vaccines: From universalization to personalization

Abstract 近年來,依靠人體免疫系統殺死腫瘤細胞已成為治療癌症的有效手段。肽疫苗的開發不僅可以打破腫瘤的免疫耐受,還可以通過特異性抗腫瘤免疫攻擊惡性細胞,由於其安全性和易於製備而在腫瘤免疫治療中受到越來越多的關注。大規模測序技術的使用使得新的腫瘤抗原的不斷發現成為可能。通過計算機模擬提高抗原決定簇預測的準確性,並利用四聚體分析,可以更輕鬆地篩选和鑑定細胞毒性淋巴細胞抗原決定簇。跨膜肽和納米顆粒技術促進了更有效的抗原攝入和傳遞。最後,從通用肽疫苗到個性化肽疫苗已經發生了相當大的演變,這種疫苗誘導了針對腫瘤新抗原的有效和特異性免疫反應。

最近,基因組分析和生物信息學方法極大地促進了針對新抗原的個性化肽疫苗的突破,從而重新引起了對該領域的興趣。此外,腫瘤肽疫苗與檢查點阻斷的組合可能會改善患者的預後。在這篇綜述中,我們討論了腫瘤肽疫苗的發展和新技術進步,從普遍化到個性化,以突出腫瘤肽疫苗在臨床癌症免疫治療中的巨大前景。 In recent years, relying on the human immune system to kill tumour cells has become an effective means of cancer treatment. The development of peptide vaccines, which not only break the immune tolerance of a tumour but also attack malignant cells via specific antitumour immunity, has received increased attention in tumour immunization therapy due to their safety and easy preparation. The use of large-scale sequencing technology enables the continuous discovery of new tumour antigens. With improved accuracy of epitope prediction by computer simulation and the usage of a tetramer assay, cytotoxic lymphocyte epitopes can be screened and identified more easily. Transmembrane peptide and nanoparticle technologies promote more effective intake and delivery of antigens. Consequently, considerable evolution from universal to personalized peptide vaccines has taken place, and such vaccines induce an efficient and specific immune response targeting tumour neoantigens. Recently, genomic analysis and bioinformatics approaches have greatly facilitated the breakthrough of personalized peptide vaccines targeting neoantigens, resulting in a renewed interest in this field. Further, the combination of tumour peptide vaccines with checkpoint blockades may improve patient outcomes. In this review, we discuss the development of tumour peptide vaccines and the new technological progress, from universalization to personalization, to highlight the substantial promise of tumour peptide vaccines in clinical cancer immunotherapy.


>>閱讀全文

4 次瀏覽0 則留言

最新文章

查看全部